A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration

Phase 1 Completed 8 enrolled Eyevensys

NaSequentialOpen-labelTreatment

Summary

The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD). The main question it aims to answer is: Is PST-611-CT1 safe for participants? Participants will: * Receive a single dose of PST-611 * Will be followed up for a total of 16 weeks following PST-611 administration

Timeline

Start: 2025-06-23
Primary completion: 2026-04-07
Completion: 2026-04-07

Outcome

Met primary endpoint

release “PST-611-CT1 met the primary and secondary objectives, with PST-611 demonstrating excellent safety and tolerability at both dose levels.” pulsesight.com ↗

Publications

Results Bigot K, Gondouin P, Benard R, Montagne P, Youale J, Piazza M, Picard E, Bordet T, Behar-Cohen F. Transferrin Non-Viral Gene Therapy for Treatment of Retinal Degeneration. Pharmaceutics. 2020 Sep 1;12(9):836. doi: 10.3390/pharmaceutics12090836.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PST-611	Other / unclassified	—	Intramuscular